AI-assisted non-contrast CT for detecting multiple cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of an AI-assisted non-contrast CT imaging model for screening multiple types of cancer, including lung, liver, gastric, colorectal, esophageal, pancreatic, and breast cancers. It aims to enroll 1 million asymptomatic participants who will undergo routine health examinations at designated centers in China. The AI model will automatically detect cancerous lesions, and positive cases will be referred for further imaging and care according to established guidelines. The goal is to improve early detection rates and treatment outcomes for these cancers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Subject is able and willing to provide informed consent and sign an informed consent form.
2. Subject has undergone an abdominal or chest non-contrast CT scan.

Exclusion Criteria:

1. Subject has been diagnosed with one of the following cancers within the last five years: lung, liver, stomach, colon, esophageal, pancreatic, or breast cancer;
2. Subject has any medical condition that contraindicates high-resolution MRI/CT/Endoscopy;
3. Subject cannot be followed up or is participating in other clinical trials.

Where it's running

• Changhai Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Wang Beilei, M.D.
• Email: lilly_wang@126.com
• Phone: 86-13774238083

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SL-28 for Advanced Solid Tumours

  A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Second Life Therapeutics · Sydney, New South Wales and 2 other locations · NCT07341737

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• IDOV-Immune for advanced solid tumors

  This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.

  Recruiting at 5 sites Phase 1 ViroMissile, Inc. · St Louis, Missouri and 4 other locations · NCT06910657

• Evaluating zanidatamab for HER2-expressing tumors

  This study is testing a new drug called zanidatamab to see if it can help people with certain types of cancer that have high levels of HER2 and who have already tried other treatments without success.

  Recruiting at 30 sites Phase 2 Jazz Pharmaceuticals · Prescott, Arizona and 41 other locations · NCT06695845

• Using brodalumab to treat immune-related side effects from cancer therapy

  This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06673329

• Evaluating AGX101 for advanced solid tumors

  This study is testing a new drug called AGX101 to see if it can help people with advanced solid tumors who haven't had success with other treatments.

  Recruiting at 7 sites Phase 1 Angiex, Inc. · Los Angeles, California and 6 other locations · NCT06440005

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.